ExpreS2ion Biotech: Opsummering fra fysisk investorseminar
ExpreS2ion Biotech var tidligere på ugen repræsenteret af selskabets CEO Bent U. Frandsen på et HCA investorseminar. Fokus i præsentationen var rettet mod selskabets teknologiplatform med særligt fokus på deres vaccinekandidat mod brystkræft, herunder markedspotentialet, vaccinedesign, klinisk data, sammenligning med nuværende produkter samt mulig tidslinje og design af fase 1 studier.
Se præsentationen (PDF) her: Link
HC Andersen Capital modtager betaling fra ExpreS2ion Biotech or en Digital IR/Corporate Visibility abonnementsaftale. /Michael Friis kl. 09:00, d. 22-09-2024.
ExpreS2ion Biotech Holding
ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.
Read more on company page